ArticleNeurology(R) neuroimmunology & neuroinflammation2021
Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
Open access · goldAbstract readCase Reports
In one paragraph
Article in Neurology(R) neuroimmunology & neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis.Neurology · 2026Article
- Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis.Frontiers in immunology · 2026Article
- De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.Brain : a journal of neurology · 2025Review
- Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy.Drug design, development and therapy · 2024Review
- High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.CNS drugs · 2022Review
- The 2022 Lady Estelle Wolfson lectureship on neurofilaments.Journal of neurochemistry · 2022Review
- Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.International journal of molecular sciences · 2022Review
- Progressive multifocal leukoencephalopathy in a patient with mediastinal teratoma: a case report.BMC neurology · 2022Article
- Comparative effectiveness of natalizumabTherapeutic advances in neurological disorders · 2022Article
- Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies.Current neuropharmacology · 2022Article
- Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry.Scientific reports · 2021Article
- Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology.Therapeutics and clinical risk management · 2021Review
- Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 3 countries.
Alyssa A TooropFrom the Department of Neurology (A.A.T., Z.Y.G.L., E.E.M.S., B.A.J., Z.L.E.K., J.K.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam; Department of Clinical Chemistry (C.E.T.), Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam; Department of Ophthalmology (A.P.), Neuro-ophthalmology Expertise Center, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hanover Medical School, Hanover, Germany; Department of Radiology and Nuclear Medicine (M.P.W., F.B.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam, the Netherlands; Department of Neuroinflammation (F.B.), Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (F.B.), London, United Kingdom. a.toorop@amsterdamumc.nl.ORCID 0000-0002-7196-9826
Zoë Y G van LieropFrom the Department of Neurology (A.A.T., Z.Y.G.L., E.E.M.S., B.A.J., Z.L.E.K., J.K.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam; Department of Clinical Chemistry (C.E.T.), Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam; Department of Ophthalmology (A.P.), Neuro-ophthalmology Expertise Center, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hanover Medical School, Hanover, Germany; Department of Radiology and Nuclear Medicine (M.P.W., F.B.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam, the Netherlands; Department of Neuroinflammation (F.B.), Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (F.B.), London, United Kingdom.ORCID 0000-0003-3200-8966
Eva E M StrijbisFrom the Department of Neurology (A.A.T., Z.Y.G.L., E.E.M.S., B.A.J., Z.L.E.K., J.K.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam; Department of Clinical Chemistry (C.E.T.), Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam; Department of Ophthalmology (A.P.), Neuro-ophthalmology Expertise Center, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hanover Medical School, Hanover, Germany; Department of Radiology and Nuclear Medicine (M.P.W., F.B.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam, the Netherlands; Department of Neuroinflammation (F.B.), Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (F.B.), London, United Kingdom.ORCID 0000-0001-6705-5864
Charlotte E TeunissenFrom the Department of Neurology (A.A.T., Z.Y.G.L., E.E.M.S., B.A.J., Z.L.E.K., J.K.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam; Department of Clinical Chemistry (C.E.T.), Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam; Department of Ophthalmology (A.P.), Neuro-ophthalmology Expertise Center, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hanover Medical School, Hanover, Germany; Department of Radiology and Nuclear Medicine (M.P.W., F.B.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam, the Netherlands; Department of Neuroinflammation (F.B.), Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (F.B.), London, United Kingdom.ORCID 0000-0002-4061-0837
Axel PetzoldFrom the Department of Neurology (A.A.T., Z.Y.G.L., E.E.M.S., B.A.J., Z.L.E.K., J.K.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam; Department of Clinical Chemistry (C.E.T.), Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam; Department of Ophthalmology (A.P.), Neuro-ophthalmology Expertise Center, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hanover Medical School, Hanover, Germany; Department of Radiology and Nuclear Medicine (M.P.W., F.B.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam, the Netherlands; Department of Neuroinflammation (F.B.), Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (F.B.), London, United Kingdom.ORCID 0000-0002-0344-9749
Mike P WattjesFrom the Department of Neurology (A.A.T., Z.Y.G.L., E.E.M.S., B.A.J., Z.L.E.K., J.K.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam; Department of Clinical Chemistry (C.E.T.), Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam; Department of Ophthalmology (A.P.), Neuro-ophthalmology Expertise Center, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hanover Medical School, Hanover, Germany; Department of Radiology and Nuclear Medicine (M.P.W., F.B.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam, the Netherlands; Department of Neuroinflammation (F.B.), Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (F.B.), London, United Kingdom.ORCID 0000-0001-9298-2897
Frederik BarkhofFrom the Department of Neurology (A.A.T., Z.Y.G.L., E.E.M.S., B.A.J., Z.L.E.K., J.K.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam; Department of Clinical Chemistry (C.E.T.), Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam; Department of Ophthalmology (A.P.), Neuro-ophthalmology Expertise Center, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hanover Medical School, Hanover, Germany; Department of Radiology and Nuclear Medicine (M.P.W., F.B.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam, the Netherlands; Department of Neuroinflammation (F.B.), Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (F.B.), London, United Kingdom.ORCID 0000-0003-3543-3706
Brigit A de JongFrom the Department of Neurology (A.A.T., Z.Y.G.L., E.E.M.S., B.A.J., Z.L.E.K., J.K.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam; Department of Clinical Chemistry (C.E.T.), Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam; Department of Ophthalmology (A.P.), Neuro-ophthalmology Expertise Center, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hanover Medical School, Hanover, Germany; Department of Radiology and Nuclear Medicine (M.P.W., F.B.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam, the Netherlands; Department of Neuroinflammation (F.B.), Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (F.B.), London, United Kingdom.
Zoé L E van KempenFrom the Department of Neurology (A.A.T., Z.Y.G.L., E.E.M.S., B.A.J., Z.L.E.K., J.K.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam; Department of Clinical Chemistry (C.E.T.), Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam; Department of Ophthalmology (A.P.), Neuro-ophthalmology Expertise Center, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hanover Medical School, Hanover, Germany; Department of Radiology and Nuclear Medicine (M.P.W., F.B.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam, the Netherlands; Department of Neuroinflammation (F.B.), Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (F.B.), London, United Kingdom.ORCID 0000-0001-9557-5381
Joep KillesteinFrom the Department of Neurology (A.A.T., Z.Y.G.L., E.E.M.S., B.A.J., Z.L.E.K., J.K.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam; Department of Clinical Chemistry (C.E.T.), Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam; Department of Ophthalmology (A.P.), Neuro-ophthalmology Expertise Center, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hanover Medical School, Hanover, Germany; Department of Radiology and Nuclear Medicine (M.P.W., F.B.), Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam, the Netherlands; Department of Neuroinflammation (F.B.), Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (F.B.), London, United Kingdom.ORCID 0000-0002-6347-5957
Medizinische Hochschule Hannover · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the disease course of carryover progressive multifocal leukoencephalopathy (PML) after switching from natalizumab to ocrelizumab in 2 patients with relapsing-remitting MS.
methodsTwo case reports with 1 year of follow-up and retrospective longitudinal measurements of serum neurofilament light (NfL) levels and B-cells.
resultsPML was diagnosed 78 days (case 1) and 97 days (case 2) after discontinuation of natalizumab. Both patients developed mild immune reconstitution inflammatory syndrome (IRIS) despite B-cell depletion caused by ocrelizumab. NfL levels increased in both patients during PML-IRIS. PML-IRIS lesions stabilized after treatment with mefloquine and mirtazapine, followed by methylprednisolone, and both patients continued therapy with ocrelizumab when B-cells started to repopulate.
conclusionsThe clinical course of carryover PML was mild in both patients, suggesting that B-cell depletion possibly did not aggravate PML-IRIS in these 2 patients.
Indexed as
AdultAntibodies, Monoclonal, HumanizedHumansImmunologic FactorsLeukoencephalopathy, Progressive MultifocalMaleMultiple Sclerosis, Relapsing-RemittingNatalizumabAntibodies, Monoclonal, HumanizedImmunologic FactorsNatalizumabocrelizumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.